Daiichi and Merck saw the highest ORR—57.1%—in patients who received the top dose of R-DXd. Yet the drugmakers have opted to ...

Roche believes it has exited phase 3 with data to support talks with regulatory agencies, but the mixed results raise ...

Cancer treatment developer HistoSonics reeled in $250 million in an oversubscribed series D round of financing two months ...

Leverage RWE strategically to build regulator-ready submissions.

Exelixis’ oral tyrosine kinase inhibitor (TKI) was tied to a 20% reduced risk of death from colorectal cancer, appearing to ...

Two European-based biotechs—Indivi of Switzerland and Clouds of Care of Belgium—have inked a collaboration deal with the goal of leveraging precision medicine tools to boost the early phase of ...

Cancer biotech Vivace Therapeutics is tuning up for a phase 3 trial after its potential first-in-class small molecule scored ...

GSK may be happy with the latest readouts from two Hansoh-partnered antibody-drug conjugates, but the Big Pharma’s oncology R ...

Tubulis’ next-generation antibody-drug conjugate (ADC) has been tied to an overall response rate (ORR) of 59% as the German ...

Sophia Genetics has launched an artificial-intelligence-powered tool that creates virtual copies of patients, known as ...

Roche’s giredestrant was shown to reduce the risk of breast cancer progression or death by 62% for a specific cohort of a ...

Europe’s leading cancer conference may be swimming in antibody-drug conjugate data, but AstraZeneca remains convinced that ...